// App-Quantinova.ai

P1-01-02 : Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study

Researchers

Presenter

  • J-Y Pierga

Principal Investigators

  • O Tredant

  • M Chevrier

  • C Dubot

  • V Lorgis

  • G Romieu

  • A Goncalves

  • M Debled

  • C Levy

  • J-M Ferrero

  • C Jouannaud

  • E Luporsi

  • M-A Mouret-Reynier

  • F Dalenc

  • F Berger

  • J Lemonnier

  • C Proudhon

  • F-C Bidard

Medical Centers

  • Institut Jean-Godinot, Reims, France

  • Centre Alexis Vautrin, Vandoeuvre-Les-Nancy, France

  • Centre Jean Perrin, Clermont-Ferrand, France

  • Institut Claudius Regaud, Toulouse, France

  • Institut Paoli-Calmettes, Marseille, France

  • Centre Leon Berard, Lyon, France

  • UNICANCER, Paris, France

  • Centre Francois Baclesse, Caen, France

  • Centre Antoine-Lacassagne, Nice, France

  • Center Georges-Francois Leclerc, Dijon, France

  • Institut du Cancer de Montpellier, Montpellier, France

  • Institut Curie, Paris Cedex, France

  • Institut Curie, Saint-Cloud, AB, France

  • Institut Bergonie, Bordeaux, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Cancer antigen 15-3

  • Carcinoembryonic antigen

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

  • Lactate dehydrogenase

  • Circulating DNA

Drug/Treatment

  • Bevacizumab

  • Paclitaxel

  • Alora

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved